G31.86
Alexander disease
Clinical Classification Guidelines
Medical Intelligence & Overview
Alexander disease is a rare and serious neurological disorder that primarily affects the brain's white matter. It is classified as a leukodystrophy, a group of genetic conditions that cause the progressive destruction of myelin, the protective covering of nerve fibers. Named after the physician who first described it, Dr. W. Stewart Alexander, this disease predominantly appears in infants and young children but can also occur in adolescents and adults. Due to its rarity and complexity, Alexander disease can present with a variety of neurological symptoms, making early diagnosis and management crucial for affected individuals.
Causes & Symptoms
Clinical Causes: Genetic mutations in the GFAP gene, which encodes glial fibrillary acidic protein Inheritance pattern is usually autosomal dominant, meaning only one copy of the mutated gene is needed for the disease to manifest Mutations lead to abnormal accumulation of GFAP in astrocytes, resulting in damage to nervous tissue No environmental or lifestyle factors have been conclusively linked to the development of Alexander disease
Key Symptoms: Progressive difficulty with movement and coordination (ataxia) Enlarged head size (macrocephaly), especially in infants Seizures or abnormal brain activity Stiff or spastic muscles Delayed developmental milestones Poor feeding and difficulty swallowing in infants Weakness or paralysis in limbs Loss of motor skills over time Seizures Cognitive decline and changes in behavior
Diagnostic & Treatment
Diagnosis Path: The diagnosis of Alexander disease involves a combination of clinical evaluation, neuroimaging, and genetic testing: - **Clinical assessment**: Observation of neurological symptoms and developmental history - **Neuroimaging**: Magnetic resonance imaging (MRI) reveals specific features such as frontal lobe white matter abnormalities, brainstem and spinal cord involvement, and at times, characteristic cystic changes. - **Genetic testing**: Identification of pathogenic mutations in the GFAP gene confirms the diagnosis. - **Additional tests**: Lumbar puncture and other laboratory evaluations may be conducted to rule out other conditions. Due to overlapping symptoms with other neurological disorders, comprehensive testing is essential for an accurate diagnosis.
Treatment Protocols: Currently, there is no cure for Alexander disease. Management focuses on alleviating symptoms and providing supportive care: - **Symptom management**: Use of medications to control seizures, spasticity, and other neurological issues. - **Supportive therapies**: - Physical therapy to improve movement and strength - Occupational therapy to assist with daily activities - Speech therapy for communication and swallowing difficulties - **Nutritional support**: Special feeding techniques or nutritional supplementation for infants experiencing feeding difficulties. - **Monitoring and supportive care**: Regular neurological assessments and supportive measures to address complications arising from the disease. Research is ongoing to better understand and potentially develop targeted treatments for Alexander disease, including gene therapy and molecular approaches.
Clinical Advice & FAQs
Billing Guidance
Is G31.86 a billable ICD-10 code?
Yes, G31.86 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G31.86?
Clinical documentation must specify the nature of Alexander disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference